Duchenne Muscular Dystrophy

Treatment by Exon skipping

Antisense oligonucleotides

Tricyclo-DNA

 

Our mission

To implement therapeutically aimed R&D programs for Duchenne Muscular Dystrophy and other genetic diseases for which no satisfying treatment yet exists

 

 

 

Our values

Research

SQY Therapeutics conducts innovative R&D projects with a therapeutic aim

Engagement

A passionate team of researchers devoted to the patient cause

Integrity

The social purpose of our company takes precedence over its commercial valuation

The Patients

To broaden the field of application of our innovations to other pathologies

Our specificity

 

SQY Therapeutics is a singular scientific and human enterprise born from the meeting of researchers and parents of children affected by an incurable disease: Duchenne Muscular Dystrophy.

It is the result of many years of struggle by parents to identify and promote the development of an effective treatment to save their children.

Founded in 2015, SQY Therapeutics is a technological platform intended to design, develop and produce antisense oligonucleotide molecules for the correction of certain mutations using “exon skipping”. Several molecules are under development, for other pathologies as well, through collaborations and/or partnerships.

The company is managed by parents of patients affected by Duchenne Muscular Dystrophy.

 

Logo sqy ombre

About the Team

Equipe SQY THERAPETUCIS

 

SQY Therapeutics team

Today the company employs highly qualified collaborators, doctors of biology and chemistry, research engineers, as well as many expert consultants in the domains of organic chemistry of nucleic acids, molecular genetics, preclinical evaluation of candidate compounds and their clinical development.
Highly competent in neuromuscular disease research, the team is mainly dedicated to the development of therapeutic approaches based on targeted modulation of mRNA splicing through antisense oligonucleotides in the tricyclo-DNA family.
SQY Therapeutics is the only tricyclo-DNA class oligonucleotide manufacturing synthesis platform that also integrates a preclinical evaluation activity dedicated to this type of molecule.
The SQY Therapeutics headquarters is based in Noisy le Roi, in the Yvelines, and its R&D activity is located in the UFR santé Simone Veil at the Université de Versailles in Montigny-le-Bretonneux where it works alongside the U1179 Inserm-UVSQ mixed research unit.

The Avance 1 clinical trial

Approval to start Avance1 clinical trial: enrolment of patients

The Avance1 clinical trial application filed by SQY Therapeutics received an approval from the ANSM (National Agency for Medicinal Safety and Health Products), number EU CT 2022-500703-49-01. Patient recruitment started.

Title of the study :

  • Phase 1/2-a Clinical trial : DMD children and adults with a genetically confirmed diagnosis of Duchenne Muscular Dystrophy, eligible for exon 51 skipping
  • Objective : open label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of SQY51
  • Phase 1 duration : 13 weeks multiple dose escalation
  • Phase 2a duration : 32 weeks
  • Administration : intravenous injections
  • Monocentric : Hôpital Raymond Poincaré, Garches (92380)
  • Launch : 2023
  • Trial coordinator : Adeline Vulin, SQY Therapeutics
  • Trial promotor : SQY Therapeutics.
  • Entity responsible of the trial: Garches Clinical Investigations Center.
  • Main investigator : Professor Helge AMTHOR (Service Pédiatrie/Centre de référence des maladies neuromusculaires, Hospital Raymond Poincaré of Garches, University of Versailles Saint-Quentin-en-Yvelines).
Logo sqy ombre
sqy therapeutics projet avance 1
sqy projet avance 1
SQY therapeutics projet avance 1

The SQY51 candidate compound

Developed by SQY Therapeutics, it is an antisense oligonucleotide (15-mer) of the tricyclo-DNA class.

SQY51 is designed to hybridize with exon 51 of the dystrophin pre-messenger RNA to restore an operational reading frame by "exon skipping" in Duchenne Muscular Dystrophy patients with an appropriate deletion pattern (i.e., ≈10% of the DMD population).

Preclinical data of the Avance 1 clinical trial

Preclinical work in non-human primates and mice confirms the strong potential of this compound: (i) the preclinical safety profile is very favorable, (ii) the candidate compound is efficiently distributed throughout the musculature (skeletal muscles, in particular respiratory muscles, and the heart - priority targets in DMD), (iii) the levels of exon 51 skip in all tissues analyzed are such that they suggest the possibility of a real clinical benefit in DMD patients.

The designers of the Avance 1 trial

SQY Therapeutics

A human and scientific adventure